Galileo – Biotech Innovation Fund BC USD

Reference Data

ISIN LU2226244361
Valor Number
Bloomberg Global ID
Fund Name Galileo – Biotech Innovation Fund BC USD
Fund Provider IPConcept (Luxemburg) S.A. Zürich, Switzerland
Phone: +352 260248-1
E-Mail: info.lu@ipconcept.com
Web: www.ipconcept.com
Fund Provider IPConcept (Luxemburg) S.A.
Representative in Switzerland IPConcept (Schweiz) AG
Zürich
Phone: +41 044 224 32 09
Distributor(s) Bellecapital AG
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets)
Redemption Condition The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel)
Investment Strategy *** The objective of the investment policy for the sub-fund is to achieve an appropriate level of growth in the sub-fund currency while taking the investment risk into account. The sub-fund is actively managed. The composition of the portfolio is determined by the Fund Manager solely in accordance with the criteria laid down in the investment objectives / the investment policy, is regularly reviewed and, if necessary, adjusted. The sub-fund is not managed using an index as a benchmark.
Peculiarities

Fund Prices

Current Price * 47.26 USD 17.09.2025
Previous Price * 46.96 USD 16.09.2025
52 Week High * 58.72 USD 20.09.2024
52 Week Low * 33.21 USD 09.04.2025
NAV * 47.26 USD 17.09.2025
Issue Price * 47.26 USD 17.09.2025
Redemption Price * 47.26 USD 17.09.2025
Closing Price *
Indicative Minimum Price
Fund Assets *** 30,307,563
Unit/Share Assets *** 29,263,360
Trading Information SIX

Performance

YTD Performance +0.62% 30.12.2024
17.09.2025
YTD Performance (in CHF) -12.52% 30.12.2024
17.09.2025
1 month +1.68% 18.08.2025
17.09.2025
3 months +17.56% 17.06.2025
17.09.2025
6 months +10.91% 17.03.2025
17.09.2025
1 year -17.72% 17.09.2024
17.09.2025
2 years -9.57% 18.09.2023
17.09.2025
3 years -35.89% 19.09.2022
17.09.2025
5 years -68.49% 31.03.2021
17.09.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Krystal Biotech Inc 9.62%
Arcellx Inc 7.65%
Vertex Pharmaceuticals Inc 5.20%
Alnylam Pharmaceuticals Inc 4.95%
BioNTech SE ADR 4.68%
Regeneron Pharmaceuticals Inc 4.40%
Sarepta Therapeutics Inc 3.05%
Stoke Therapeutics Inc 2.88%
Moderna Inc 2.82%
Beam Therapeutics Inc 2.63%
Last data update 28.02.2025

Cost / Risk

TER *** 0.47%
TER date *** 30.06.2025
Performance Fee ***
PTR
Max. Management Fee ***
Ongoing Charges *** 0.44%
SRRI ***
SRRI date *** 31.08.2025

Breakdowns

Equity Countries ***

Equity Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)